ClinicalTrials.gg
RecruitingNCT06984627Updated Oct 28, 2026

A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

A Phase 2 interventional study of Rilzabrutinib dose 1 and Rilzabrutinib dose 2 in Graves' Disease, sponsored by Sanofi. Recruiting at 24 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 28, 2026First sites in 4 new countriesSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Graves Disease with a site in Italy — 6 open to participants now, 9 under way, 1 of them phase 3. Graves Disease · Italy.

Planned enrollment
10th of 11
30 · median 60
Started
2025
with 2 others
Phase 2
5 of 14
3 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Sanofi

Among the 14 studies in Graves Disease with a site in Italy, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 10th registered.

Graves Disease

162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.

Browse Graves Disease studies →

Open to participants now

6 of the 14 studies in Graves Disease with a site in Italy are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Graves Disease with a site in Italy, or all of them as a file.
02

Study summary

This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.

Study details include:

  • Screening period (up to 4 weeks).
  • Treatment period (up to 16 weeks).
  • Follow-up period (4 weeks). The number of visits will be up to 13.
03

Conditions studied

  • Graves' Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have a confirmed diagnosis of Graves' disease with active hyperthyroidism, with or without active Graves' orbitopathy at the time of screening.
  • A subset of participants will have a diagnosis of active Graves' orbitopathy, as confirmed by ophthalmic exam at screening and a clinical activity score (CAS) ≥3 for the most severely affected eye, and associated with one or more of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, proptosis ≥2 mm, and/or intermittent or constant diplopia.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • History of hyperthyroidism not caused by Graves' disease (eg, hyperthyroidism due to toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis).
  • History of thyroid storm or at high risk of developing thyroid storm as determined by evaluating clinician.
  • Enlarged thyroid goiter causing upper airway obstruction and/or requiring surgical intervention during the study period.
  • For participant with Graves' orbitopathy, requires immediate surgical ophthalmological intervention or is planning corrective surgery/irradiation during the course of the study.
  • Sight threatening Graves' orbitopathy or decreased visual acuity due to optic neuropathy within the last 6 months.
  • Corneal decompensation unresponsive to medical management.
  • Onset of Graves' orbitopathy symptoms >9 months prior to baseline.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Rilzabrutinib dose 1

    Rilzabrutinib

    Drug: Rilzabrutinib dose 1

  • Experimental
    Rilzabrutinib dose 2

    Rilzabrutinib

    Drug: Rilzabrutinib dose 2

Interventions

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: SAR444671

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: SAR444671

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in FT4 levels

    Free thyroxine

    Time frame: At Week16

Secondary outcomes

  1. Percent change from baseline in FT3 levels

    Free triiodothyronine

    Time frame: At Week16

  2. Proportion of participants with FT4 levels within normal limits

    Time frame: At Week16

  3. Proportion of participants with FT3 levels within normal limits

    Time frame: At Week16

  4. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and withdrawals due to TEAEs during the study period

    Time frame: Up to week 20

07

Study locations

19 of 24 sites recruiting
  • Investigational Site Number : 0320002
    Buenos Aires, 1061, Argentina
    Recruiting
  • Investigational Site Number : 0320001
    Buenos Aires, 1119, Argentina
    Recruiting
  • Investigational Site Number : 0320003
    Córdoba, 5000, Argentina
    Recruiting
  • Investigational Site Number : 1240003
    Calgary, Alberta T2N 4L7, Canada
    Recruiting
  • Investigational Site Number : 1240002
    Surrey, British Columbia V3T 4G8, Canada
    Recruiting
  • Investigational Site Number : 1240001
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
  • Investigational Site Number : 1520001
    Concepción, Biobio 4070566, Chile
    Recruiting
  • Investigational Site Number : 1520002
    Iquique, Tarapacá \t765000, Chile
    Recruiting
  • Investigational Site Number : 2760002
    Essen, 45147, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 2760001
    Frankfurt, 60590, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 3000002
    Athens, 115 27, Greece
    Recruiting
  • Investigational Site Number : 3000001
    Athens, 124 62, Greece
    Recruiting
  • Investigational Site Number : 3000003
    Larissa, 411 10, Greece
    Recruiting
  • Investigational Site Number : 3480001
    Pécs, 7624, Hungary
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 3800001
    Milan, Milano 20122, Italy
    Recruiting
  • Investigational Site Number : 3800004
    Milan, Milano 20132, Italy
    Recruiting
  • Investigational Site Number : 3800005
    Merano, 39012, Italy
    Recruiting
  • Investigational Site Number : 3800003
    Palermo, 90127, Italy
    Recruiting
  • Investigational Site Number : 3800002
    Pisa, 56126, Italy
    Recruiting
  • Investigational Site Number : 7240002
    Barcelona, Catalunya [Cataluña] 08036, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 7240001
    Pamplona, Navarre 31008, Spain
    Completed

    Not enrolling at this site — choose another above.

  • Investigational Site Number : 7240004
    Seville, Sevilla 41009, Spain
    Recruiting
  • Investigational Site Number : 8260003
    Milton Keynes, Buckinghamshire MK6 5LD, United Kingdom
    Recruiting
  • Investigational Site Number : 8260001
    Newcastle upon Tyne, England NE2 4HH, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Aug 2026 → Feb 2027 and completion Sep 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 22, 2025
StartActual
Sep 2, 2025
Primary completionEst.
Feb 11, 2027was Aug 2026
CompletionEst.
Mar 11, 2027was Sep 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 1 site removed — first sites in Argentina, Chile, Greece and Hungary. 5 sites changed recruiting status (4 now completed, 1 now active, not recruiting)
Show 5 sites
  • Investigational Site Number : 7240002 · Barcelona, SpainRecruiting→Completed
  • Investigational Site Number : 7240001 · Pamplona, SpainRecruiting→Completed
  • Investigational Site Number : 2760002 · Essen, GermanyRecruiting→Completed
  • Investigational Site Number : 2760001 · Frankfurt, GermanyRecruiting→Completed
  • Investigational Site Number : 3480001 · Pécs, HungaryRecruiting→Active, not recruiting
Show 10 added (3 Argentina, 3 Greece, 2 Chile, 1 Hungary, 1 Italy)
  • Investigational Site Number : 0320002 · Buenos Aires, Argentina
  • Investigational Site Number : 0320001 · Buenos Aires, Argentina
  • Investigational Site Number : 0320003 · Córdoba, Argentina
  • Investigational Site Number : 1520001 · Concepción, Chile
  • Investigational Site Number : 1520002 · Iquique, Chile
  • Investigational Site Number : 3000002 · Athens, Greece
  • Investigational Site Number : 3000001 · Athens, Greece
  • Investigational Site Number : 3000003 · Larissa, Greece
  • Investigational Site Number : 3480001 · Pécs, Hungary
  • Investigational Site Number : 3800005 · Merano, Italy
Show 1 removed
  • Investigational Site Number : 3800005 · Merano, Italy
across 2 updates, Oct 1, 2026 – Oct 28, 2026
Primary completion
Aug 25, 2026→Feb 11, 2027
Oct 1, 2026
Study completion
Sep 23, 2026→Mar 11, 2027
Oct 1, 2026
Show all 2 updates
  1. Oct 28, 2026
    3 sites changed recruiting status (2 now completed, 1 now active, not recruiting)
    Show 3 sites
    • Investigational Site Number : 2760002 · Essen, GermanyRecruiting→Completed
    • Investigational Site Number : 2760001 · Frankfurt, GermanyRecruiting→Completed
    • Investigational Site Number : 3480001 · Pécs, HungaryRecruiting→Active, not recruiting
    + 2 other changes: verification date and references
  2. Oct 1, 2026
    10 sites added, 1 site removed — first sites in Argentina, Chile, Greece and Hungary. 2 sites changed recruiting status (2 now completed)
    Show 2 sites
    • Investigational Site Number : 7240002 · Barcelona, SpainRecruiting→Completed
    • Investigational Site Number : 7240001 · Pamplona, SpainRecruiting→Completed
    Show 10 added (3 Argentina, 3 Greece, 2 Chile, 1 Hungary, 1 Italy)
    • Investigational Site Number : 0320002 · Buenos Aires, Argentina
    • Investigational Site Number : 0320001 · Buenos Aires, Argentina
    • Investigational Site Number : 0320003 · Córdoba, Argentina
    • Investigational Site Number : 1520001 · Concepción, Chile
    • Investigational Site Number : 1520002 · Iquique, Chile
    • Investigational Site Number : 3000002 · Athens, Greece
    • Investigational Site Number : 3000001 · Athens, Greece
    • Investigational Site Number : 3000003 · Larissa, Greece
    • Investigational Site Number : 3480001 · Pécs, Hungary
    • Investigational Site Number : 3800005 · Merano, Italy
    Show 1 removed
    • Investigational Site Number : 3800005 · Merano, Italy
    Primary completion Aug 25, 2026→Feb 11, 2027
    Study completion Sep 23, 2026→Mar 11, 2027
    + 3 other changes: identifiers, verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06984627
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Sep 2, 2025
Primary completion
Feb 11, 2027 (estimated)
Completion
Mar 11, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion